Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes?
The optimal treatment of type 2 diabetes is currently uncertain. This article reviews a new class of oral hypoglycaemic agents: dipeptidyl peptidase-IV inhibitors. By potentiating the action of incretins they offer a more 'physiological' control of blood sugar with fewer side effects, and the possibility of ameliorating the decline in beta cell function.
McIntyre
Hugh F
HF
Department of Medicine, Conquest Hospital, Hastings, East Sussex.
Grant
Paul
P
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005749:Gastric Inhibitory Polypeptide / Q000187:drug effects; D052216:Glucagon-Like Peptide 1 / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D054795:Incretins / Q000378:metabolism*; D016896:Treatment Outcome
D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1